Noventure
Noventure is a Barcelona-based medical device IP company that licenses clinically backed, MDR Class III-certified brands (Tasectan, Utipro Plus, Ulkox) built on proprietary natural-polymer barrier technology to exclusive distribution partners across 50+ countries, addressing diarrhea, UTIs, and wound care via pharmacy channels.
- Company typePrivate
- Founded2014
- HeadquartersBarcelona, Spain
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Noventure does
Noventure, S.L. is a Barcelona-based medical device IP company that develops and licenses clinically backed healthcare brands built on a proprietary barrier technology platform. The company's core technology rests on natural polymers — xyloglucan, gelatin tannate, gelose, and Olea europaea leaf extract — that form protective films over mucosal epithelia and modulate wound microenvironments, addressing acute diarrhea (Tasectan AF, Tasectan Duo, Xilaplus AF), uncomplicated urinary tract infections (Utipro Plus AF), anal fissure healing (Ulkox), IBS-D (Gelsectan), rhinitis (Rhinosectan), and hard-to-heal skin ulcers (Oleoabrax EHO). All primary products are CE-marked and comply with MDR Class III (or Class IIb for Ulkox), and the products are supported by randomized controlled trials with two included in leading European treatment guidelines (EAU cystitis guidelines, German GPGN pediatric gastroenterology guidelines).
The company operates an asset-light licensing model and does not sell directly. Noventure grants exclusive territorial commercial rights to regional distribution partners (Devicare in Spain, RFSU in the Nordics, Pharmaforce across Denmark/Sweden/Finland/Norway, Salvat in Iberia, Therabel in France, Montavit in Austria, Jadran in Russia, Medexport in Kazakhstan, and others), and partners commercialize products through pharmacy channels under local brand names. Products reach over 50 countries and the Tasectan franchise alone sold 3.7 million packs (51+ million standard units) through licensees in 34 countries during 2023.
Noventure is privately held, was founded in 2014, has 11-50 employees, and discloses no institutional ownership or parent company. The customer base is B2B — distribution partners rather than end users — and revenue derives from licensing royalties on partner net sales. Geographic and therapeutic-area expansion is active, with new registrations in Central Asia (2025), recent licensee additions across Eastern Europe, and continued portfolio broadening via the 2021 acquisition of Ulkox and Oleoabrax wound-healing products.
Noventure firmographics
Firmographics- Name
- Noventure
- Legal name
- Noventure, S.L.
- Website
- https://noventure.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Noventure is a Barcelona-based medical device IP company that licenses clinically backed, MDR Class III-certified brands (Tasectan, Utipro Plus, Ulkox) built on proprietary natural-polymer barrier technology to exclusive distribution partners across 50+ countries, addressing diarrhea, UTIs, and wound care via pharmacy channels.
- Ownership category
- akta.pro rank
Noventure industry classification
Industry- Product category
- Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Pharmaceutical Distributors (HLAIAJAB)
- akta.pro secondary industry
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
Keywords
Where Noventure is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
Noventure business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Marketing or Sales, Personnel, Others
Revenue model
- Licensing Royalties: Noventure's business model is based on licensing exclusive commercial rights for medical device products to distribution partners in selected geographic regions. Partners commercialize products under various local brand names and pay licensing fees or royalties to Noventure.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Noventure product offering
Product offeringCore offering
Noventure develops, patents, and licenses a portfolio of CE-marked, MDR Class III medical devices based on proprietary barrier technology using natural polymers (xyloglucan, gelatin tannate, gelose, Olea europaea leaf extract). Core products treat acute diarrhoea (Tasectan AF), urinary tract infections (Utipro Plus AF), and anal fissures (Ulkox), with additional wound-healing, nasal, and IBS-D products. The company does not sell directly; instead it grants exclusive commercial distribution rights to regional pharmaceutical partners who commercialize the products under local brand names through pharmacies in over 50 countries.
Product overview
Noventure is a Barcelona-based medical device company operating a multi-brand portfolio of clinically proven healthcare products. The core portfolio consists of three primary CE-marked medical devices: Tasectan AF (MDR Class III) for acute diarrhea, Utipro Plus AF (MDR Class III) for urinary tract infections, and Ulkox (MDR Class IIb) for anal fissure healing. All products are backed by clinical trials, included in treatment guidelines, and protected by patents. The company also markets acquired wound-healing products (Oleoabrax EHO), nasal mucoprotection (Rhinosectan), pediatric diarrhea formulations (Xilaplus AF), probiotic combinations (Tasectan Duo), and IBS-D treatment (Gelsectan). Noventure's business model is based on licensing distribution rights to regional partner companies, with products distributed across over 50 countries.
Differentiator
Problem solved
Functional benefit
Brands
- Tasectan: Medical device for treatment of acute diarrhoea, composed of xyloglucan and gelose. MDR Class III certified.
- Tasectan Duo
- Utipro Plus / Utipro Plus AF
- Ulkox
- Xilaplus / Xilaplus AF
- Gelsectan
- Rhinosectan / Rinonet
- Oleoabrax
- Aprotecol
Products and services
- Tasectan AF CE-marked, MDR Class III medical device composed of xyloglucan (tamarind seed extract) and gelose that forms a protective film over the intestinal mucosa to reduce frequency and duration of acute diarrhoea in children (under 3 years up to 14 years, sachets) and adults (capsules). Licensed to exclusive distribution partners worldwide.
- Utipro Plus AF CE-marked, MDR Class III medical device based on xyloglucan and gelose that creates a protective mechanical barrier in the intestinal lumen to impair bacterial contact with mucosa, prevent adhesion of uropathogenic bacteria, and reduce recurrent urinary tract infections in adolescents (14+ years) and adults. Mentioned in EAU guidelines as non-antibiotic approach with highest level of scientific evidence.
- Ulkox CE-marked, MDR Class IIb medical device based on Fucocert (polysaccharide), glycerine, Olea europaea leaf extract, and Carbopol 980 presented as hydrogel for the healing of anal fissures in children and adults. Components act synergistically by moisturizing the wound, scavenging free radicals, isolating the lesion, and reducing pH.
- Oleoabrax EHO CE-marked medical device based on Olea europaea leaf extract hydrogel (EHO-85) intended for healing of full and partial thickness wounds including pressure ulcers, venous leg ulcers, and diabetic foot ulcers. Demonstrated 51.6% relative wound area reduction versus 18.9% for standard hydrogel in clinical trials.
- Rhinosectan Class I CE-marked medical device based on xyloglucan (mucomimetic agent) that forms a protective barrier over the nasal epithelial mucosa for control and treatment of rhinitis and rhinosinusitis symptoms.
- Xilaplus AF
Quantifiable outcome
- Tasectan demonstrated reduction of stool frequency and improved stool consistency in children with acute diarrhea in randomized controlled trials
- +2 more outcomes
Companies that use Noventure
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles1 record
Noventure technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Noventure partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and regional.
- Laboratorios Salvat, S.A.coreSalvat distributes Noventure's nasal mucoprotection product (Rhinosectan) in Spain and Portugal. The product is a Class I CE marked medical device based on xyloglucan for control and treatment of rhinitis and rhinosinusitis symptoms.
- RFSU (Riksförbundet för sexuell upplysning)coreRFSU distributes Noventure's Utipro Plus in Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). With this agreement, Utipro Plus became available in 21 European countries. RFSU is a Swedish Association for Sexuality Education and NGO founded in 1933, focused on women's health.
- Devicare, S.L.coreNew partnership announced to bring Utipro Plus AF into the Spanish market. Noventure collaborates with Devicare to expand product availability in Spain.
- PharmaforcecoreNoventure granted Pharmaforce exclusive distribution right for Tasectan AF in the Nordic markets (Denmark, Sweden, Finland, and Norway). Tasectan AF is intended to restore physiological functions of intestinal walls for control and reduction of diarrheal events.
- VemediaregionalVemedia distributes Utipro Plus in the Netherlands and France (under the umbrella brand Cysticare/Utipro plus).
- LapidotregionalLapidot is a long-term distribution partner for Utipro Plus in Israel since Q4 2017.
- JGLregionalJGL distributes Tasectan in Croatia under the brand Normia Stop. Tasectan acts by forming a film that protects intestinal mucosa, reducing frequency and duration of diarrhea episodes.
- TherabelregionalTherabel is a long-term partner distributing Xilaplus in France under the brand name Diastil Diarrhee.
- Generica IlaçregionalNew partnership with Generica Ilaç to market Xilaplus AF in Turkey. Xilaplus AF is a Class IIa CE marked medical device for control and reduction of diarrheal events.
- MedexportregionalMedexport signed an agreement for distribution of Utipro Plus AF in Kazakhstan, representing expansion into Central Asia.
- PamexregionalPamex extends distribution of Utipro Plus AF to the UK, building on their existing partnership in Ireland.
- MiecysregionalMiecys distributes Xilaplus in Estonia, Latvia, and Lithuania.
- MontavitregionalMontavit distributes Tasectan Duo in Austria (second market after Italy by Angelini). Tasectan Duo is the first combination of gelatin tannate and inactivated bacteria.
- JadranregionalJadran distributes Tasectan in Russia under the umbrella brand Adiarin. It was the first Noventure product launched in Russia.
- ELVAregionalELVA launches Utipro Plus in Czech Republic, Slovak Republic, and Hungary.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Noventure competitors and assessment
Company assessmentDirect peers
- Ferring Pharmaceuticals: Swiss specialty pharma with strong focus on gastroenterology, urology, and reproductive health — directly overlapping with Noventure's therapeutic categories. Comparable specialty-pharma profile with patent-protected products and a global licensing/partner approach.
- Tillotts Pharma AG: Swiss specialty pharma focused on gastroenterology (IBD, infectious diarrhea). Comparable size to Noventure with a similar specialty medical-device product strategy and European licensing/commercial model.
- BioGaia AB: Swedish probiotics and gut-health consumer healthcare company. Comparable in therapeutic focus (gut health), consumer/medical positioning, and global partner-driven distribution model with multiple brand SKUs.
Broad incumbents
- Menarini Group: Italian pharmaceutical group with strong consumer health and distribution network across Europe and emerging markets. Comparable mid-to-large European specialty pharma with deep licensing and distribution partnerships.
- Almirall S.A. Spanish specialty pharma with focus on dermatology and specialty care. Comparable as a Spanish-headquartered specialty pharma with European commercial reach and licensing partnerships in adjacent therapeutic areas.
- Italfarmaco S.p.A. Italian specialty pharma with focus on women's health, neurology, and rare diseases. Comparable specialty/OTC profile and European licensing approach, particularly relevant for women's health (UTIs).
- Chiesi Farmaceutici S.p.A. Italian specialty pharma with focus on respiratory, neonatology, and rare diseases. Comparable European specialty-pharma profile and global licensing/partner approach.
- Smith & Nephew plc: Global medical device company with a significant wound management franchise. Comparable to Noventure's wound-care portfolio (Ulkox/Oleoabrax) in the chronic-wound-care segment, though much larger scale.
- Angelini Pharma: Italian specialty pharma with consumer health/OTC portfolio and licensing partnerships. Comparable specialty-medtech and licensing-driven distribution model across Europe and the Mediterranean.
- Recordati S.p.A. Italian specialty pharma with European focus on rare diseases, urology, and specialty care. Comparable specialty pharma of similar size range operating through licensing and partner distribution in Europe.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Noventure social profiles
Digital presenceNoventure compliance and trust
Trust signalCompliance6 records
Noventure financial estimates
Financial estimateRevenue estimate
Valuation estimate
Noventure leadership team
Management profileNumber of profiles
Profiles1 record
Noventure funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Noventure M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Noventure
What does Noventure do?
Noventure develops, patents, and licenses a portfolio of CE-marked, MDR Class III medical devices based on proprietary barrier technology using natural polymers (xyloglucan, gelatin tannate, gelose, Olea europaea leaf extract). Core products treat acute diarrhoea (Tasectan AF), urinary tract infections (Utipro Plus AF), and anal fissures (Ulkox), with additional wound-healing, nasal, and IBS-D products. The company does not sell directly; instead it grants exclusive commercial distribution rights to regional pharmaceutical partners who commercialize the products under local brand names through pharmacies in over 50 countries.
Is Noventure a public or private company?
Noventure is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Noventure founded?
Noventure was founded in 2014. It employs 11 to 50 people.
Where is Noventure based?
Noventure is headquartered in Barcelona, Spain, in the Europe region.
How does Noventure make money?
One revenue line is on record: licensing Royalties.
Who are Noventure's main competitors?
Direct peers on record are Ferring Pharmaceuticals, Tillotts Pharma AG and BioGaia AB. Broad incumbents are Menarini Group, Almirall S.A., Italfarmaco S.p.A., Chiesi Farmaceutici S.p.A., Smith & Nephew plc, Angelini Pharma and Recordati S.p.A..
Does Noventure have an API?
No public API is recorded for Noventure.
What industry is Noventure in?
Noventure's product category is Medical Devices. Its primary akta.pro industry code is HLAIAJAB, Specialty Pharmaceutical Distributors, with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 339112 and its SIC code is 3841.